Erik is an associate in the Commercial IP team and advises clients on a range of non-contentious IP matters. His experience includes drafting and negotiating complex IP licences and options, R&D collaboration agreements, contract development and manufacturing arrangements and litigation settlement agreements.
In addition, Erik works on general commercial matters including the supply of goods and services, distribution arrangements and consultancy agreements. Erik advises regularly on the formation of spin-outs from universities and research institutes and provides IP support on corporate transactions.
Erik’s work spans a number of industries, with a particular focus on the life sciences sector where his clients range from newly established biotechs, multi-national pharmaceutical companies and medical device manufacturers to investment funds and world-class academic institutions. Erik’s interest in providing commercial advice to players in the life sciences ecosystem is complemented by his background in biochemistry and biophysics.
During his time at Bristows, Erik has gained valuable experience working alongside in-house counsel as part of client secondments to a global biopharmaceutical company, a world-leading genomics research institute and the technology transfer office of a leading London university.
- BSc, Biochemistry, University of Bristol
- MRes, Molecular Biophysics, King’s College London
- Qualified 2018
What others say
“Bristows was a valued partner in the success of making our vision become a reality.”Stephanie Morris, Director of Industry Partnerships and Commercialisation at Imperial College London
“They enabled a very positive conclusion to the overall deal.”Richard Fagan, Director of BioPharma at UCL Business
“Their expertise made them the perfect partner to work with on the highly complex Apollo transaction.”Richard Fagan, Director of BioPharma at UCL Business
“UCLB has worked with Bristows for over 25 years, in relation to intellectual property licensing transactions as well as corporate transactions such as spinout formation.”Richard Fagan, Director of BioPharma at UCL Business
“Bristows’ knowledge of the life sciences market and players, as well as their licensing expertise, was invaluable as we navigated this complex transaction.”Iain Thomas, Cambridge Enterprise’s Head of Life Sciences